Biotech Archives - Page 63 of 795

2 minute read

Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025

April 18, 12:50 PM

Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025.

LLY

2 minute read

Once Valued At Billions, 23andMe’s CEO Considers Privatization To Secure Company’s Future

By Vandana Singh

April 18, 12:06 PM

Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a focus shift to drug development, the move seeks funding for potential breakthroughs.

GSK

2 minute read

FDA Classifies Boston Scientific’s Recall For Device To Stop Blood Flow As ‘Most Serious’

By Vandana Singh

April 18, 10:02 AM

Boston Scientific announces a Class I recall of Obsidio Embolic due to high-risk implications for lower GI bleeding embolization. Potential adverse effects include bowel ischemia, necessitating major surgery or resulting in prolonged hospitalization.

AXNX

2 minute read

Oncternal Announces First Patient Dosed In Fourth Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer

By Benzinga Newsdesk

April 18, 9:04 AM

Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of

ONCT

1 minute read

Dario Signs Two Employers For Cardiometabolic Suite With Integrated GLP-1 Solution, Beginning In Q2 Of 2024

By Benzinga Newsdesk

April 18, 8:34 AM

Dario selected to provide integrated and proven solutions to improve employee cardiometabolic healthNEW YORK, April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the

DRIO

4 minute read

AbbVie Announces Phase 3 SELECT-GCA Study Of Upadacitinib Results In Patients With Giant Cell Arteritis; In Combination With A 26-week Steroid Taper Regimen Achieved Its Primary Endpoint Of Sustained Remission; Key Secondary Endpoints Were Also Met

By Benzinga Newsdesk

April 18, 8:32 AM

− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper

ABBV

3 minute read

YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine

By Benzinga Newsdesk

April 18, 8:11 AM

YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic

2 minute read

Actinium Highlights Ability Of Iomab-B To Overcome High-Risk TP53 Mutation Resulting In Improvement In Overall Survival In Patients With Active Relapsed Refractory AML At The European Bone Marrow Transplant Annual Meeting

By Benzinga Newsdesk

April 18, 8:11 AM

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or

ATNM

1 minute read

BioVie To Present Data Showing How NE3107 Potentially Restores Homeostasis Via Specific Genes Associated With Dementia, Metabolism, And Inflammation

By Benzinga Newsdesk

April 18, 8:09 AM

BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today

BIVI

3 minute read

Immutep Appoints Leading Research Institute To Conduct First-in-Human Phase I Study Of IMP761

By Benzinga Newsdesk

April 18, 8:07 AM

Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune

IMMP